Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNX-1900 in chronic migraine
NCT05679908Phase 2Completed
- Sponsor
- Tonix Pharmaceuticals
- Start
- Dec 2022
- Primary completion
- Oct 2023
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of TNX-1900 in chronic migraine (3 arms), sponsored by Tonix Pharmaceuticals. Primary endpoint: Mean Change in the Number of Monthly Migraine Headache Days at 12 weeks. Started Dec 2022; status: completed.
02
Drugs
TNX-1900
03
Conditions
chronic migraine
Beyond the preview
Go deeper on NCT05679908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05679908.